Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lancet on multivitamins

This article was originally published in The Tan Sheet

Executive Summary

Panel recommendations from the National Institutes of Health provide an opportunity for physicians to educate patients about nutrition, according to an editorial in The Lancet May 27. The independent panel determined May 17 that there currently is too little evidence to support - or advise against - the use of multivitamin and mineral supplements for the prevention of chronic diseases (1"The Tan Sheet" May 22, 2006, p. 6). Herein lays the chance for physicians to become better informed counselors and caregivers, The Lancet says. "Consumers need to know about the supplements and foods they choose to buy. But there is a clear role for informed medical advice to patients here too." The Lancet adds that the escalating obesity epidemic, and its impact on chronic diseases, amplifies the need for nutritional counseling to figure more prominently in medical school curricula. "Doctors must tackle their patients not only about how much they eat, but also what they eat," the journal reports...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts